Outcome of neuropsychiatric symptoms related to an antiretroviral drug following its substitution by nevirapine: the RELAX study

Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy

(2013) Zara Shubber et al.   AIDS

Rilpivirine Versus Efavirenz in HIV-1–Infected Subjects Receiving Emtricitabine/Tenofovir DF: Pooled 96-Week Data from ECHO and THRIVE Studies

(2013) M.R. Nelson et al.   HIV CLINICAL TRIALS

Durable Efficacy and Safety of Raltegravir Versus Efavirenz When Combined With Tenofovir/Emtricitabine in Treatment-Naive HIV-1–Infected Patients

(2013) Jürgen K. Rockstroh et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Persistence of novel first-line antiretroviral regimes in a cohort of HIV-positive subjects, CoRIS 2008–2010

(2012) Inma Jarrin et al.   ANTIVIRAL THERAPY

Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study

(2012) Abdel G Babiker et al.   Clinical Trials

Week 96 Efficacy, Virology and Safety of Darunavir/r Versus Lopinavir/r in Treatment-Experienced Patients in TITAN

(2012) Denes Banhegyi et al.   CURRENT HIV RESEARCH

Antiretroviral Treatment of Adult HIV Infection

(2012) Melanie A. Thompson et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naive HIV-1-infected patients

(2011) Joseph Gathe et al.   ANTIVIRAL THERAPY

Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial

(2011) Vicente Soriano et al.   ANTIVIRAL THERAPY

Open-Label Randomized Multicenter Selection Study of Once Daily Antiretroviral Treatment Regimen Comparing Ritonavir-Boosted Atazanavir to Efavirenz with Fixed-Dose Abacavir and Lamivudine

(2011) Miwako Honda et al.   INTERNAL MEDICINE

A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected population

(2010) Mark Nelson et al.   AIDS

Substitution of Nevirapine because of Efavirenz Toxicity in AIDS Clinical Trials Group A5095

(2010) Jeffrey T. Schouten et al.   CLINICAL INFECTIOUS DISEASES

Efficacy and Safety of Maraviroc Versus Efavirenz, Both With Zidovudine/Lamivudine: 96-Week Results From the MERIT Study

(2010) Juan Sierra-Madero et al.   HIV CLINICAL TRIALS